RYTM officer exercises 3,350 options, sells shares at $105

Rhythm Pharmaceuticals (RYTM) reported an insider equity transaction by its Chief Human Resources Officer.

Rhea-AI Filing Summary

Rhythm Pharmaceuticals (RYTM) reported an insider equity transaction by its Chief Human Resources Officer. On 11/20/2025, the officer exercised 3,350 stock options at an exercise price of $27.35 per share and acquired the same number of common shares. On the same date, 3,350 common shares were sold at a price of $105 per share under a pre-arranged Rule 10b5-1 trading plan adopted on August 7, 2025.

After these transactions, the officer beneficially owned 20,814 shares of common stock directly and held 11,725 stock options that remain beneficially owned. The options exercised on November 20, 2025 were part of a grant made on February 1, 2023 that vests in 16 substantially equal quarterly installments, tied to continued service with the company.

Insider Trade Summary

Exercise and Sale: 3,350 shares ($260K approx. pre-tax spread)

Exercise and Sale 3 txns

Insider Cramer Pamela J.

Role Chief Human Resources Officer

Sold 3,350 shs ($352K)

Approx. gross sale proceeds $352K

Approx. exercise cost $92K

Approx. pre-tax spread $260K

Type	Security	Shares	Price	Value
Exercise	Stock Options (Right to Buy)	3,350	$0.00	$0.00
Exercise	Common Stock	3,350	$27.35	$92K
Sale	Common Stock	3,350	$105.00	$352K

Holdings After Transaction: Stock Options (Right to Buy) — 11,725 contracts (Direct); Common Stock — 20,814 shares (Direct)

Footnotes (2)

1. F1. The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 7, 2025.
2. F2. The stock options were granted on February 1, 2023. The options vest and become exercisable in 16 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer following the grant date.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Rhythm Pharmaceuticals (RYTM) disclose in this Form 4?

The filing shows the Chief Human Resources Officer exercised 3,350 stock options at $27.35 per share and sold 3,350 common shares at $105 per share on 11/20/2025.

How many Rhythm Pharmaceuticals (RYTM) shares does the officer own after the transaction?

Following the reported trades, the officer directly beneficially owned 20,814 shares of Rhythm Pharmaceuticals common stock.

How many stock options does the Rhythm Pharmaceuticals (RYTM) officer still hold?

After the November 20, 2025 exercise, the officer beneficially owned 11,725 stock options relating to Rhythm Pharmaceuticals common stock.

Was the sale of Rhythm Pharmaceuticals (RYTM) shares under a Rule 10b5-1 trading plan?

Yes. The 3,350-share sale was effected under a Rule 10b5-1 trading plan adopted by the reporting person on August 7, 2025.

What were the key prices in this Rhythm Pharmaceuticals (RYTM) Form 4 transaction?

The stock options had an exercise price of $27.35 per share, and the common shares sold in the same-day transaction were sold at $105 per share.

When were the reported Rhythm Pharmaceuticals (RYTM) stock options originally granted and how do they vest?

The stock options were granted on February 1, 2023 and vest in 16 substantially equal installments for each three full months of successive service after the grant date.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 11/24/2025 - 04:15 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Cramer Pamela J.

(Last) (First) (Middle)

C/O RHYTHM PHARMACEUTICALS, INC.

222 BERKELEY STREET, 12TH FLOOR

(Street)

BOSTON MA 02116

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
RHYTHM PHARMACEUTICALS, INC. [ RYTM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Human Resources Officer

3. Date of Earliest Transaction (Month/Day/Year)
11/20/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	11/20/2025		M		3,350	A	$27.35	24,164	D
Common Stock	11/20/2025		S(1)		3,350	D	$105	20,814	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Options (Right to Buy)	$27.35	11/20/2025		M			3,350	(2)	01/31/2033	Common Stock	3,350	$0	11,725	D

Explanation of Responses:

1. The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 7, 2025.

2. The stock options were granted on February 1, 2023. The options vest and become exercisable in 16 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer following the grant date.

	/s/ Stephen Vander Stoep, attorney-in-fact for Pamela J. Cramer	11/24/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.